CRAVES FRED B

Average Profitability
<0.0001%
Insider Buys Quantity
4
Insider Buys Sum
$2.05M
Insider Sells Quantity
8
Insider Sells Sum
$138.67M

Insider Activity of CRAVES FRED B

According to the SEC Form 4 filings, CRAVES FRED B, being in a position of

  1. director at Madrigal Pharmaceuticals, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 29489 shares for $7.11M,
    over all time since 2018-06-11, has bought 2000 shares for $249,387, and sold 1265397 shares for $138.67M.

The largest purchase of all time was on 2014-10-08 and amounted to 69112 shares of Journey Medical Corporation for $1.11M.

The largest sale of all time was on 2019-12-13 and amounted to 1200000 shares of Madrigal Pharmaceuticals, Inc. for $126.56M.

Biography of CRAVES FRED B

No biography is available at this moment.

2024-12-03SaleMadrigal Pharmaceuticals, Inc.
MDGL
director
3,600
0.0162%
$315.31$1.14M-3.23%
2024-11-25SaleMadrigal Pharmaceuticals, Inc.
MDGL
director
3,400
0.0156%
$350.30$1.19M-8.53%
2024-05-14SaleMadrigal Pharmaceuticals, Inc.
MDGL
director
22,489
0.1065%
$212.88$4.79M+20.54%
2020-08-19SaleMadrigal Pharmaceuticals, Inc.
MDGL
7,303
0.0475%
$107.64$786,095+9.17%
2020-08-18SaleMadrigal Pharmaceuticals, Inc.
MDGL
10,197
0.0666%
$110.03$1.12M+7.24%
2020-08-17SaleMadrigal Pharmaceuticals, Inc.
MDGL
12,500
0.0806%
$110.73$1.38M+5.17%
2019-12-13SaleMadrigal Pharmaceuticals, Inc.
MDGL
1.2M
8.4176%
$105.47$126.56M+8.9%
2018-11-19PurchaseMadrigal Pharmaceuticals, Inc.
MDGL
2,000
0.014%
$124.69$249,387-14.18%
2018-06-11SaleMadrigal Pharmaceuticals, Inc.
MDGL
5,908
0.0431%
$287.46$1.7M-50.82%
2017-08-14PurchaseJourney Medical Corporation
DERM
10,000
0.1983%
$23.95$239,460
2017-08-10PurchaseJourney Medical Corporation
DERM
20,000
0.3739%
$22.57$451,470
2014-10-08PurchaseJourney Medical Corporation
DERM
director
69,112
0.9158%
$16.00$1.11M
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.